Will skin 'paste' replace skin grafts as the future of tending to burns? New technique takes tiny patch of skin and grows up to 500 times its original size
Doctors have developed a technique to treat severe burns using a paste made from tiny fragments of a patient's skin. (Source: the Mail online | Health)
Source: the Mail online | Health - November 25, 2023 Category: Consumer Health News Source Type: news
Scientists print functional SKIN for the first time, giving hope to burn victims and wounded veterans
Doctors have found a way to use 3D printing technology to engineer human skin grafts in the lab that have been proven to heal wounds quicker and decrease scarring. (Source: the Mail online | Health)
Source: the Mail online | Health - October 4, 2023 Category: Consumer Health News Source Type: news
A 10-year single-burn center review of free tissue transfer for burn-related injuries - Alessandri Bonetti M, Jeong T, Stofman GM, Egro FM.
Skin grafting is the mainstay treatment in burn patients. However, in the scenario of soft tissue deficit along with exposure of critical structures, free flap is the only reconstructive option to provide adequate coverage. The aim of the study is to revie... (Source: SafetyLit)
Source: SafetyLit - September 19, 2023 Category: International Medicine & Public Health Tags: Burns, Electricity, Explosions, Fire, Scalds Source Type: news
How Are Keloids Treated?
Discussion Wound healing is a complex process and abnormalities are common. Hypertrophic or keloid scarring are the two types of excessive scarring with both having excessive scar tissue that is elevated above the normal skin. Hypertrophic scarring occurs usually only within the wound and can regress. They are common after burns and develop within 3 months of skin injury. Keloid scarring spreads beyond the original wound and does not regress, and often recur. They can occur even 1 year after injury. Keloids have an incidence of 5-15%. “Compared to normal fibroblasts, keloidal fibroblasts have longer lives, higher pro...
Source: PediatricEducation.org - July 17, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Can ‘toxic’ bilirubin treat a variety of illnesses?
Generations of medical and biology students have been instilled with a dim view of bilirubin. Spawned when the body trashes old red blood cells, the molecule is harmful refuse and a sign of illness. High blood levels cause jaundice, which turns the eyes and skin yellow and can signal liver trouble. Newborns can’t process the compound, and although high levels normally subside, a persistent surplus can cause brain damage. Yet later this year up to 40 healthy Australian volunteers may begin receiving infusions of the supposedly good-for-nothing molecule. They will be participating in a phase 1 safety trial, sponsored...
Source: ScienceNOW - June 8, 2023 Category: Science Source Type: news
Fish Skin Graft vs Standard of Care in Diabetic Foot Ulcers Fish Skin Graft vs Standard of Care in Diabetic Foot Ulcers
How effective are fish skin grafts in the treatment of chronic diabetic foot ulcers, and what are the cost benefits over that of standard of care?Wounds (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 5, 2023 Category: Consumer Health News Tags: General Surgery Journal Article Source Type: news
Jay Leno Jokes That His Facial Skin Grafts After Car Fire Was Foreskin: ‘When I Get Excited…Well, Never Mind’
Six months after suffering serious burns to his face during a fire in his car garage, Jay Leno hilariously explained to Chris Wallace where his skin grafts came from. And the comedian still knows how to land a punch line. “People think that skin grafts are expensive,” Leno said on Friday’s episode…#jayleno #chriswallace #whostalking #jewish #grossmanburncenter (Source: Reuters: Health)
Source: Reuters: Health - June 3, 2023 Category: Consumer Health News Source Type: news
Prevalence of non-accidental burns and related factors in children: a systematic review and meta-analysis - Hamza Hermis A, Tehrany PM, Hosseini SJ, Firooz M, Hosseini SR, Jamshidbeigi A, Zaboli Mahdiabadi M, Ghorbani Vajargah P, Mollaei A, Karkhah S, Takasi P, Alizadeh Otaghvar H, Farzan R.
Non-accidental burns (NABs) in children had some adverse effects, such as severe burns, requiring skin grafting, and mortality. Previous studies reported NABs in the form of neglect, suspected abuse, and child abuse. Also, different statistics were estimat... (Source: SafetyLit)
Source: SafetyLit - May 26, 2023 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
Chlorhexidine Dressings for Skin Graft Donor Site Wounds Chlorhexidine Dressings for Skin Graft Donor Site Wounds
How do these dressings compare in the management of skin graft donor area wounds?Wounds (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 8, 2023 Category: Consumer Health News Tags: Plastic Surgery & Aesthetic Medicine Journal Article Source Type: news
NPWTi and Split-Thickness Skin Graft for a Venous Leg Ulcer NPWTi and Split-Thickness Skin Graft for a Venous Leg Ulcer
In this report, a chronic venous leg ulcer was successfully treated with NPWT with instillation combined with split-thickness skin graft.Wounds (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 24, 2023 Category: Consumer Health News Tags: General Surgery Journal Article Source Type: news
Update on IMBRUVICA ® (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications
HORSHAM, Pa., April 6, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics, an AbbVie Company, announced today the intent to voluntarily withdraw the U.S. indications for IMBRUVICA® (ibrutinib) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, and for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. This decision was made in consultation with the U.S. Food and Drug Administration (FDA), c...
Source: Johnson and Johnson - April 6, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Engineering skin grafts for complex body parts
Scientists successfully grew new skin in the shape of a human hand that was also stronger than standard engineered skin grafts. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - February 14, 2023 Category: Consumer Health News Source Type: news
Upper Lip Lift Excision as Graft for Philtrum Reconstruction Upper Lip Lift Excision as Graft for Philtrum Reconstruction
This report describes two cases where the upper lip lift was used as a full-thickness skin graft for reconstruction after Mohs surgery.ePlasty (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 6, 2023 Category: Surgery Tags: Plastic Surgery & Aesthetic Medicine Journal Article Source Type: news
Real-World Study Shows Patients Treated with IMBRUVICA ® (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a real-world study showing that patients with chronic lymphocytic leukemia (CLL) treated with first-line acalabrutinib monotherapy were 89 percent more likely to start a next-line treatment than those treated with IMBRUVICA® (ibrutinib). These data suggest the potential that first-line treatment with IMBRUVICA® in routine practice may provide patients with the ability to use once-daily, all-oral IMBRUVICA® as a monotherapy treatment for a longer period without the need to start the next line of ...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA ® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new four-year follow-up results from the Phase 3 GLOW study (Abstract #93), which showed investigational, fixed-duration treatment with IMBRUVICA® + venetoclax (I+V) reduced the risk of progression or death by 79 percent among older and/or unfit patients with previously untreated chronic lymphocytic leukemia (CLL) compared to patients treated with chemoimmunotherapy.[i] These results were highlighted in an oral presentation during the 2022 American Society of Hematology (ASH) Annual Meeting.1CLL is the most com...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news